Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-EN Version v12-EN
Language English English
Date Updated 2017-10-13 2017-10-10
Drug Identification Number 00060208 00060208
Brand name SODIUM CHLORIDE 0.9% INJ 900MG/100ML USP SODIUM CHLORIDE 0.9% INJ 900MG/100ML USP
Common or Proper name 0.9% Sodium Chloride Injection, USP 0.9% Sodium Chloride Injection, USP
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients SODIUM CHLORIDE SODIUM CHLORIDE
Strength(s) 900MG 900MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 50mL, 100mL 50mL, 100mL
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2017-08-15 2017-08-15
Actual start date 2017-08-15 2017-08-15
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments For further questions regarding this product, please contact Baxter Customer Service at 1-888-719-9955 or Medical Information at 1-855-584-1368. Customers can use the following alternate code upon their clinical judgement: JB1322P- 0.9% Sodium Chloride 250 ml For further questions regarding this product, please contact Baxter Customer Service at 1-888-719-9955 or Medical Information at 1-855-584-1368. Customers can use the following alternate code upon their clinical judgement: JB1322P- 0.9% Sodium Chloride 250 ml
Health Canada comments